Implementation of Addiction Programs: Challenges for Pain Management


TODD D. MOLFENTER, PH.D.

Center for Health Enhancement Studies (CHESS)/NIATx
University of Wisconsin- Madison

Pain Management/Buprenorphine Link

 Pain Management: One of many roads to Buprenorphine (MAT)

 PMDP Requirements, Opioid Prescribing Guidelines, & Increased Awareness



Building Capacity

• NIATx Center:

Center for Health Enhancement System Studies (CHESS)

University of Wisconsin – Madison Department of Engineering

- Seven State-Based MAT Projects (5 Buprenorphine, 2 Vivitrol)
- One Researched Based in Ohio



Sequence of Buprenorphine Barriers - Ohio

NIDA 5R01DA030431-04 To Test A Payer/Treatment Agency Intervention to Increase Use of Buprenorphine

Theme	2012/13		2015
Funds to Pay for Buprenorphine	Strong Barrier	>	Limited Barrier
Anti- pharmacotherapy Attitudes	SUD Provider Concerns	→	Community- Based Concerns
Buprenorphine Prescribing Capacity	Strong Barrier		Strong Barrier

Sequence of Buprenorphine Barriers - 2017

1R01DA0414150-01 (PI: Molfenter)

Test of a Workforce Development Intervention to Expand Buprenorphine Prescribers

Florida – Ohio - Wisconsin

Tier 1

- Prescriber Capacity
- Funding (State Specific)
- Immediate Access



Sequence of Buprenorphine Barriers - 2017

Tier 2

- Counselor Capacity
- Education of Other Stakeholders
- Documentation Turnkey

Payer-Provider Model to Implement the EVP Buprenorphine

Need = Concerns with Opioid Misuse in Ohio (2011)

Gaps = EVP Adoption Rate & Role of Payer

Low use of Opioid Treatment Medications



NIDA 5R01DA030431-04

To Test A Payer/Treatment Agency Intervention to Increase Use of Buprenorphine

Treatment Design

Baseline 2012, Intervention 2013 & 2014, Sustainability 2015

Payer Roles

- Partner with Providers
- Levers: Financing;
 Purchasing; Regulatory
 & Policy; Operations
 Management

Provider Roles

- Partner with Payer
- NIATx Model

Partnering Roles & TA

- Annual Meetings
- Monthly Coach Calls
- Monthly Payer/Provider Calls
- Coach Site Visit

Control

Baseline & Run-in 2012, Intervention 2013 & 2014, Sustainability 2015

Payer Roles

Partner with Providers

Levers: Financing;
 Purchasing; Regulatory
 & Policy; Operations
 Management

Provider Roles

- Partner with Payer
- NIATx Model

Partnering Roles & TA

- Annual Meetings
- Monthly Coach Calls
- Monthly
 Payer/Provider Calls

NIATx Model Overview

Principle	Action Step
Executive Leadership	Assign an Executive Sponsor
Change Leader	Assign an Internal Change Leader
Customer Focus	Conduct a Process Walk-through
Ideas from Outside the	Provide Source for New External Ideas
Organization	
Pilot Tests	Conduct Pilot and/or PDSA Tests

Results

Phases	% Buprenorphine Use for Patients w/Opioid Addiction Dx.		Treatment Effect	
	Control	Treatment	OR	p-Value
Baseline	10.89%	8.77%	.78	.366
Intervention	19.64%	28.47%	1.65	.000
Sustainability	18.62%	25.33%	1.48	.000

5 Principles of the NIATx Model

Principle

Executive Leadership

Change Leader

Customer Focus (Patient/Staff)

Ideas from Outside the

Organization

Pilot Tests

NIATx Principles Analysis

% Buprenorphine Use = Exec. Lead., Change Leader., Staff
Focus, Patient Focus, Outside Ideas,
& Pilot Tests

Regression Results

Year	R-Square	Sig.
2012 (Baseline)	.200	.207
2014	.362	.036

5 Principles Analysis

DV = % Buprenorphine Use

Predictors = Exec. Lead., Change Lead., Staff, Patient, Outside Ideas, & Pilot Tests

Year	R-Square	Sig.	Stepwise	Sig.
2012 (Baseline)	.200	.207	Staff Needs	.004
2014	.362	.036	Leadership	.000

5 Principles Analysis

5-Point Likert Scale

NIATx Principle	Baseline	End of Intervention	p-Value
Executive Leadership	1.89	3.50	.000
Change Leader	3.39	3.45	.460
Patient Customer Focus	1.78	3.30	.002
Staff Customer Focus	3.36	3.75	.004
Outside Ideas	2.88	3.21	.011
Rapid Cycles/Pilot Tests	2.05	3.32	.001

Workforce Development Grant

- Current R01 in place to increase buprenorphine prescribing capacity in Florida, Ohio, & Wisconsin
- Working with Health Systems, FQHCs, & Community-Base SUD Providers

 Develop a Physician Recruitment and Retention Bundle



1R01DA0414150-01 (PI: Molfenter)
Test of a Workforce Development Intervention to Expand
Buprenorphine Prescribers

Prescriber Recruitment Bundle

- Candidate Identification Strategies
- Community Prescriber Forums
- Academic Detailing
- Physician Friendly Buprenorphine Delivery Model
- Telemedicine

Future Directions

- Need for non-SUD specialty Bup prescribers
- Study affect of more MAT on opioid outcomes/mortality
- Deeper Payer Research

Questions?